83/100B115.550
USD
6.14
(5.61%)
Post Trading·115.230USD-0.320(-0.28%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
Q4 FY2026 · Earnings report
EPS estimate 1.64Revenue estimate 13.22B
Abbott Laboratories financials
Yes. Abbott Laboratories earned 4.70B USD of net income over the last twelve months, 9.7% of its revenue. It made a profit in 41 of its 41 fiscal years since 1985.
- Revenue (TTM)
- 48.23B USD
- Net income (TTM)
- 4.70B USD
- Free cash flow (TTM)
- 8.72B USD
- Cash and short-term investments
- 5.60B USD
- Total debt
- 32.61B USD
- Shareholders' equity
- 51.11B USD
Cash, debt and equity as of 30 Jun 2026.
Abbott Laboratories earnings
Next earnings · Q4 FY2026
EPS estimate
1.64 USD
Revenue estimate
13.22B USD
Last quarter · Q3 FY2026
EPS1.42Beat 0.0%Revenue13.01BBeat +0.2%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 1.54 | — | — | +8.22% | 13.75B | — | — | +5.64% | |
| Q2 FY2027 | 1.43 | — | — | +9.25% | 13.32B | — | — | +5.75% | |
| Q1 FY2027 | 1.23 | — | — | +6.98% | 12.58B | — | — | +12.65% | |
| Q4 FY2026 | 1.64 | — | — | +9.33% | 13.22B | — | — | +15.35% | |
| Q3 FY2026 | 1.42 | 1.42 | 0.00% | +9.23% | 12.99B | 13.01B | +0.18% | +14.46% | |
| Q2 FY2026 | 1.28 | 1.31 | +2.34% | +3.97% | 12.52B | 12.59B | +0.59% | +13.02% | |
| Q1 FY2026 | 1.14 | 1.15 | +0.88% | +5.50% | 11.00B | 11.16B | +1.49% | +7.78% | |
| Q4 FY2025 | 1.50 | 1.50 | 0.00% | +11.94% | 11.80B | 11.46B | -2.89% | +4.42% | |
| Q3 FY2025 | 1.30 | 1.30 | 0.00% | +7.44% | 11.39B | 11.37B | -0.18% | +6.90% | |
| Q2 FY2025 | 1.26 | 1.26 | 0.00% | +10.53% | 11.09B | 11.14B | +0.45% | +7.37% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 6.50 | — | — | +9.55% | 57.15B | — | — | +6.47% |
| FY2027 | 5.93 | — | — | +7.56% | 53.68B | — | — | +7.38% |
| FY2026 | 5.52 | — | — | +7.13% | 49.99B | — | — | +12.77% |
| FY2025 | 5.15 | 5.15 | -0.04% | +10.28% | 44.67B | 44.33B | -0.77% | +5.67% |
| FY2024 | 4.67 | 4.67 | -0.10% | +5.18% | 42.00B | 41.95B | -0.12% | +4.59% |
| FY2023 | 4.44 | 4.44 | +0.02% | -16.85% | 40.08B | 40.11B | +0.08% | -8.12% |
| FY2022 | 5.23 | 5.34 | +2.07% | +2.50% | 43.22B | 43.65B | +0.99% | +1.34% |
Abbott Laboratories growth and profitability
Full income statement- Revenue (TTM)
- 48.23B USD
- Net income (TTM)
- 4.70B USD
- Gross margin
- 57.12%
- Operating margin
- 15.24%
- Net margin
- 9.75%
Revenue / Net income
Revenue Net income Net margin
How Abbott Laboratories makes its money
Medical Devices21.39B 48.2%
Diagnostic Products8.94B 20.2%
Nutritional Products8.45B 19.1%
Established Pharmaceutical Products5.54B 12.5%
Revenue44.33B 100.0%
Cost of revenue19.72B 44.5%
Gross profit24.61B 55.5%
Research and development2.96B 6.7%
Selling and administration12.38B 27.9%
Other operating expenses1.25B 2.8%
Operating income8.05B 18.2%
Tax1.94B 4.4%
Net income6.52B 14.7%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Abbott Laboratories revenue breakdown
By product
FY2025
48.3%Medical Devices20.2%Diagnostic Products19.1%Nutritional Products12.5%Established Pharmaceutical Products
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Medical Devices | 21.39B | 48.3% | +12.6% |
| Diagnostic Products | 8.94B | 20.2% | -4.3% |
| Nutritional Products | 8.45B | 19.1% | +0.5% |
| Established Pharmaceutical Products | 5.54B | 12.5% | +6.6% |
By region
FY2025
39.8%UNITED STATES37.2%Non-US6.4%D [E]4.4%C [N]4.4%C [H]4.4%I [N]3.4%J [P]
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| UNITED STATES | 17.13B | 39.8% | +4.9% |
| Non-US | 15.98B | 37.2% | +7.6% |
| D [E] | 2.76B | 6.4% | +8.7% |
| C [N] | 1.91B | 4.4% | -9.7% |
| C [H] | 1.87B | 4.4% | +7.1% |
| I [N] | 1.87B | 4.4% | +3.0% |
| J [P] | 1.48B | 3.4% | +2.4% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Abbott Laboratories financial health
Full balance sheet- Cash and short-term investments
- 5.60B USD
- Total debt
- 32.61B USD
- Net cash
- -27.01B USD
- Free cash flow (TTM)
- 8.72B USD
- Current ratio
- 1.38
- Debt to equity
- 0.64
- Piotroski score
- 6 / 9
- Altman Z-score
- 3.36
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Abbott Laboratories valuation
- Price to earnings ratio (TTM)
- 42.80
- Forward P/E (FY2026)
- 20.94
- Price to sales (TTM)
- 4.15
- Price to book
- 3.91
- EV / EBITDA (TTM)
- 23.37
Capital structure
Market capitalization
199.95B USD
+
Total debt
32.61B USD
−
Cash and short-term investments
5.60B USD
=
Enterprise value
226.95B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Abbott Laboratories against its own history
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Stryker, Boston Scientific, Edwards Lifesciences, GE HealthCare Technologies, and DexCom, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Highest in 5 years42.813.242.8
- Gross marginHighest in 5 years55.5%50.0%55.5%Against its peers: 5 of 6Peers' median 64.0%
- Operating marginAt its median18.2%16.0%21.4%Against its peers: 5 of 6Peers' median 19.6%
- Net marginBelow its median14.7%14.3%31.9%Against its peers: 3 of 6Peers' median 14.4%
- Return on equityLowest in 5 years12.5%12.5%28.1%Against its peers: 4 of 6Peers' median 14.5%
- Free cash flow marginAt its median16.7%12.6%20.1%Against its peers: 5 of 6Peers' median 18.2%
- Revenue growthAbove its median5.7%-8.1%24.5%Against its peers: 5 of 6Peers' median 11.5%
- EPS growthLowest in 5 years-51.3%-51.3%133.6%Against its peers: 5 of 6Peers' median 8.2%
- Debt to EBITDALowest in 5 years1.26×1.26×1.58×Against its peers: 3 of 6Peers' median 2.43×
- Current ratioLowest in 5 years1.581.581.85Against its peers: 5 of 6Peers' median 1.88
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Abbott Laboratories dividends
- Annual dividend
- 2.52 USD
- Dividend yield (indicated)
- 2.18%
- Payout ratio
- 93.33%
- Years of dividend growth
- 13
- Frequency
- Quarterly
- Last payment
- 0.63 USD
- Last ex-dividend date
- 15 Oct 2026
- Last payment date
- 16 Nov 2026
Dividends per share
Abbott Laboratories ownership
- Institutions
- 82.29%
- Institutional holders
- 3,076 (-130)
- Free float
- 99.41%
InstitutionsOthers
As of 30 Jun 2026
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q3 2026 | 0 | 4 | 400.58K | 856.50K |
| Q2 2026 | 3 | 0 | 72.98K | 829.00 |
| Q1 2026 | 3 | 6 | 1.27M | 74.75K |
| Q4 2025 | 0 | 1 | 939.00 | 3.12K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Abbott Laboratories's financials
Source: Financial Modeling Prep